4.8 Review

Induction of regulatory T cells by intravenous immunoglobulin: a bridge between adaptive and innate immunity

Journal

FRONTIERS IN IMMUNOLOGY
Volume 6, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2015.00469

Keywords

intravenous immunoglobulin; regulatory T cell; dendritic cell; autoimmunity; immune modulation; cytokine

Categories

Funding

  1. Talecris
  2. Grifols Bioscience
  3. Canadian Institutes for Health Research [CIHR] [ISO115295, MOP67211]
  4. Research Institute of the McGill University Health Centre (RI-MUHC)
  5. Fonds de recherche du Quebec - Sante (FRQS)
  6. Strauss Family Foundation
  7. CIHR Canada Graduate Scholarships Doctoral Research Award

Ask authors/readers for more resources

Intravenous immunoglobulin (IVIg) is a polyclonal immunoglobulin G preparation with potent immunomodulatory properties. The mode of action of IVIg has been investigated in multiple disease states, with various mechanisms described to account for its benefits. Recent data indicate that IVIg increases both the number and the suppressive capacity of regulatory T cells, a subpopulation of T cells that are essential for immune homeostasis. IVIg alters dendritic cell function, cytokine and chemokine networks, and T lymphocytes, leading to development of regulatory T cells. The ability of IVIg to influence Treg induction has been shown both in animal models and in human diseases. In this review, we discuss data on the potential mechanisms contributing to the interaction between IVIg and the regulatory T-cell compartment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available